Determinants of sodium removal with tidal automated peritoneal dialysis

In a comprehensive evaluation of dialysis adequacy, major attention has been recently paid to fluid and Na balance. Removal of Na has been reported to be significantly poorer with automated peritoneal dialysis (APD) than with continuous ambulatory peritoneal dialysis. Only limited data on Na removal with tidal APD have been published. We analyzed peritoneal Na mass balance in 122 separate nightly tidal APD sessions performed by 7 peritonitis-free, clinically stable, patients with negligible residual renal function (< 100 mL urine daily). Correlations with other efficiency measures [ultrafiltration (UF) and small-solute clearances], prescriptive parameters [duration of treatment, initial intraperitoneal fill volume (IPV) and its tidal percentage, and dialysate flux] and peritoneal transport status were tested in univariate and multivariate linear regression models. Removal of Na was 89 +/- 55 mmol per treatment, which correlated with UF (r = 0.29, p = 0.001) and was higher in patients with high-average transport (118 +/- 41 mmol vs. 81 +/- 56 mmol in low-average transporters, p = 0.0004), in whom a significant positive correlation was found with initial IPV and duration of treatment (r = 0.55; 95% confidence interval: 0.21 to 0.77; p = 0.0029; and r = 0.66; 95% confidence interval: 0.38 to 0.83; p = 0.0002 respectively). Removal of Na correlated weakly with UF in tidal APD and showed wide inter-patient variability. It should therefore be measured rather than roughly estimated from UF. Its magnitude exposes the anuric patient on nightly APD with a "dry" day to the risk of Na retention, unless controlled Na intake or dialytic strategies aimed at enhancing Na removal, or both, are implemented.

Suspect carbon dioxide embolism during retroperitoneoscopic adrenalectomy

During a retroperitoneoscopic adrenalectomy in the prone position, a sudden increase in end-Tidal CO2 (EtCO2) (from 42 to 68 mmHg) followed by an abrupt decrease (from 68 to 35 mmHg) was observed, concomitantly with a right adrenal vein laceration. Heart rate decreased to 30 bpm, and the systolic blood pressure decreased to 40 mmHg. The patient was slightly turned in the left lateral and Trendelenburg position and vasoactive drugs were administered. The systemic blood pressure, EtCO2, CO2 elimination (VCO2) and pulse oximetry (SpO2) progressively improved within 10 minutes and, at the end of the surgery, the blood pressure recovered from hypotension. ECG returned to normal, with sinusal rhythm and heart rate approximately 70 bpm. The patient was extubated and moved to the Intensive Care Unit (ICU). This case suggests that gas embolisms may occur during retroperitoneoscopic adrenalectomy, and acute changes in EtCO2 should alert the clinicians to these rare but potentially lethal complication. EtCO2 monitoring is essential during laparoscopy, as it may help an early detection of CO2 embolism, characterized by a transient and rapid increase in EtCO2, followed by an abrupt decrease.

Incremental peritoneal dialysis favourably compares with hemodialysis as a bridge to renal transplantation

Background. The value of incremental peritoneal dialysis (PD) as a bridge to renal transplantation (Tx) has not been specifically addressed. Methods. All consecutive Stage 5 CKD patients with at least 1 year predialysis followup, starting incremental PD or HD under our care and subsequently receiving their first renal Tx were included in this observational cohort study. Age, gender, BMI, underlying nephropathy, residual renal function (RRF) loss rate before dialysis and RRF at RRT start, comorbidity, RRT schedules and adequacy measures, dialysis-related morbidity, Tx waiting time, RRF at Tx, incidence of delayed graft function (DGF), in-hospital stay for Tx, serum creatinine at discharge and one year later were collected and compared between patients on incremental PD or HD before Tx. Results. Seventeen patients on incremental PD and 24 on HD received their first renal Tx during the study period. Age, underlying nephropathy, RRF loss rate in predialysis, RRF at the start of RRT and comorbidity did not differ significantly. While on dialysis, patients on PD had significantly lower epoetin requirements, serum phosphate, calciumxphosphate product and better RRF preservation. Delayed graft function (DGF) occurred in 12 patients (29%), 1 on incremental PD and 11 on HD. Serum creatinine at discharge and 1 year later was significantly higher in patients who had been on HD. Conclusions. In patients receiving their first renal Tx, previous incremental PD was associated with low morbidity, excellent preservation of RRF, easier attainment of adequacy targets and significantly better immediate and 1-year graft function than those observed in otherwise well-matched patients previously treated with HD.

[Hypertensive crisis in kidney patients]

The classification and management of hypertensive crisis have been recently reviewed in the context of both European and American guidelines. The key points for proper blood pressure control in severe arterial hypertension are: 1 - Distinction between urgent intervention and emergencies 2 - Choice of the best drug(s) 3 - Choice of the correct route of administration. In patients with renal disease, beside the common causes of hypertension/ hypertensive crises, kidney-specific causes should be taken into account such as renal parenchymal hypertension, renovascular hypertension, sclerodermic crises, and preeclampsia.

Abstract 899: Patterns of distant and local relapses in breast cancer patients and triple negative subgroup

Aim: In patients treated for localized breast cancer, incidence, localization, and time of recurrences were registered and analyzed with the purpose of defining possible differences in site and /or time of failures associated with triple negative histology (ER-, PgR-, ERB-B2-) .

Patients and Methods: Five hundred eighty five consecutive female patients affected by localized breast cancer treated at our department between January 1999 and December 2006 were considered. Median age was 53 years (range 27 − 84). Firty five (7.9%) patients were at Stage 0 of disease, 272 (47.6%) Stage I, 206 (36%) Stage II, and 49 (8.5%) Stage III. Fifty nine (13.5%) of 440 assessable patients resulted triple negative. All patients were treated by surgery (breast sparing 552 (94.4%), mastectomy 33 (5.6%)) plus postoperative radiation therapy at doses of 50 Gy in 5 weeks, on the breast or thoracic wall and nodal regions, plus, in the case of breast conserving surgery, 10 Gy in a week on the tumoral bed. Chemotherapy, hormonal therapy or both was administered to 170, 168 and 161 patients respectively. Time and localization of recurrences were registered and analyzed relatively to the whole population and triple negative status.

Results: At a median follow up of 61 months (range 3-137) 18 (3.1%) local and 41 (7.0%) distant relapses were registered. Thirty one (5.3%) patients died of which 23 (3.9%) for breast cancer. Sites of first distant metastasis detection were bone (25%), liver (17%), lung (15%), brain (8%). In 34% of cases the detection of metastatic disease at exordium was represented by the contemporary appearance of multiple organ involvement. The median time to distant metastasis relapse resulted 34 months (range 8 − 117) with 88% of relapses before 60 months for the whole group. However in the triple negative subgroup the rate of distant relapse resulted 13.5% and local relapse 5.1%. Median time to distant relapse was 25 (8 − 48) months. Locoregional relapses were mostly in the breast or thoracic wall (16, 89%), with fewer nodal relapses (2, 11%). The median time to locoregional relapse was 32 months (8 − 78) with 78% of relapse before than 60 months and no differences were found in the patterns of relapse between the groups.

Conclusions: In our experience localized breast cancer distal recurrences mostly involves primarily bone, liver, and lung with about one third of patients having multiple organ metastatic exordium. In triple negative subgroup there was an increased risk of distant relapse with a shorter median time. No difference in time and site patterns were found relatively to locoregional recurrences.

Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 899.

Right ventricular dysfunction in patients with end-stage renal disease

BACKGROUND

While chronic dialysis treatment has been suggested to increase pulmonary pressure values, right ventricular dysfunction (RVD) is a major cause of death in patients with end-stage renal disease. We investigated the impact of different dialysis treatments on right ventricular function.

METHODS

We examined 220 subjects grouped as follows: healthy controls (n = 100), peritoneal dialysis (PD; n = 26), hemodialysis (HD) with radial arteriovenous fistula (AVF; n = 62), and HD with brachial AVF (n = 32). Echocardiography including tissue Doppler imaging (TDI) of the right ventricle was performed in all patients.

RESULTS

Pulmonary pressure values progressively rose from controls across the 3 dialysis groups (21.7 ± 6.8, 29.7 ± 6.7, 37.9 ± 6.7 and 40.8 ± 6.6 mm Hg, respectively; p < 0.001). TDI indices of right ventricular function were more impaired in HD patients, particularly in those with brachial AVF. RVD, assessed by TDI myocardial performance index, was higher in HD patients compared with PD patients (71.3 vs. 34.6%, p < 0.001). Moreover, the prevalence of RVD further increased in patients with brachial AVF compared with the radial access (90.6 vs. 61.3%, p < 0.001).

CONCLUSIONS

Compared to DP, HD increases the risk of RVD, particularly in the presence of brachial AVF. TDI may detect early functional failure of the right ventricle in HD patients.

Radiation therapy in primary orbital lymphoma: a single institution retrospective analysis

Background

Primary orbital lymphoma is a rare disease that accounts for 10% of all orbital tumors. Radiotherapy on the orbital cavity is the treatment of choice for this unusual presentation of localized non-Hodgkin's lymphoma (NHL). The aim of this study is to retrospectively evaluate the effectiveness and the toxicity of radiation treatment in patients with primary orbital lymphoma.

Methods

Forty-seven consecutive patients having primary orbital lymphoma treated in our department between May 1983 and September 2006 were investigated in a retrospective study. Either ⁶⁰Co γ rays or 6 MV X rays were used to deliver daily fractions of 1.8 or 2.0 Gy, 5 times/week, with total doses ranging from 34.2 to 50 Gy. Forty-three patients had stage IE, three had stage II and one stage IV disease. Thirty-eight patients had marginal zone B-cell lymphoma, 5 diffuse large B cell lymphoma, 3 mantle cell lymphoma and 1 Burkitt lymphoma. Local control (LC), disease free survival (DFS), overall survival (OS) and late side effects were evaluated in all patients.

Results

With a median follow up of 45 months, LC was obtained in 100% of patients. The estimated 5- and 7-year DFS rates were 75.8% and 55.3%, and the 5- and 7-year OS rates were 88.7% and 79.9% respectively. Acute toxicity was minimal. Late toxicity such as cataract, keratitis, retinopathy and xerophthalmia occurred respectively in 12 (25.5%), 5 (10.6%), 1 (2.1%), and 9 (19.1%) patients.

Conclusion

Radiotherapy is an effective and at the same time well tolerated treatment for primary orbital lymphoma.

Incremental prognostic value of cardiac single-photon emission computed tomography after nitrate administration in patients with ischemic left ventricular dysfunction

BACKGROUND

We evaluated the incremental prognostic value of viability assessment by nitrate single-photon emission computed tomography (SPECT) in patients with ischemic left ventricular (LV) dysfunction.

METHODS AND RESULTS

One hundred and sixty-four patients with previous myocardial infarction and LV dysfunction (ejection fraction 29% +/- 15%) underwent two Tc-99m sestamibi SPECT studies, under control conditions and after sublingual nitrate administration, for evaluation of myocardial viability. In each patient, viability was defined as the presence of > or = 2 severely dysfunctional segments with preserved tracer uptake (> or = 55% of peak activity). Cardiac death, myocardial infarction, and late (> 2 months) revascularization were considered events. Follow-up was 98% complete at a mean period of 30 +/- 24 months. At baseline SPECT, 119 (73%) patients had evidence of viable myocardium, while 45 (27%) did not. Of these latter patients, 18 (40%) had evidence of viability after nitrate administration. Cardiac events occurred in 58 (35%) patients. Cumulative probability of event-free survival was similar in patients with and without viability at baseline SPECT (log rank 0.3, P = NS), while it was lower in patients with viability at nitrate SPECT compared to those without (log rank 6.3, P < .01). The addition of nitrate SPECT data significantly improved the prognostic power of the model including clinical, functional, angiographic, and baseline SPECT data (P < .01).

CONCLUSIONS

In patients with previous myocardial infarction and LV dysfunction, nitrate SPECT imaging provides incremental prognostic information over those obtained from clinical, functional, angiographic variables, and baseline SPECT data.

Lymph nodes in the irradiated field influence the yield of radiation-induced chromosomal aberrations in lymphocytes from breast cancer patients

PURPOSE

To measure chromosomal aberrations in blood lymphocytes from breast cancer patients treated with radiotherapy after quadrantectomy or tumorectomy.

METHODS AND MATERIALS

Twenty-two breast cancer patients treated with breast-conserving surgery and radiation were evaluated. Adjuvant chemotherapy was also given to 9 patients. Blood samples were obtained before radiotherapy, after about one-half of the fractions, and at the end of the treatment of the whole breast (50 Gy). Chromosome aberrations in peripheral blood lymphocytes were measured using chemical-induced premature chromosome condensation combined with fluorescence in situ hybridization.

RESULTS

Radiation treatment produced a significant increase in the yield of chromosomal aberrations. A large interindividual variability was observed. The variability was not related to field size, previous chemotherapy, or treatment morbidity. Chromosome aberrations in lymphocytes at the end of the treatment were significantly higher in the group of patients with no lymph nodes surgically removed before the treatment than in the group of patients with more than 10 lymph nodes removed.

CONCLUSION

The number of lymph nodes within the radiation field is an important factor affecting the yield of radiation-induced chromosomal aberrations in breast cancer patients.

Early treatment of benign prostatic hyperplasia: implications for reducing the risk of permanent bladder damage

A significant change has occurred in the management of symptomatic benign prostatic hyperplasia (BPH) since effective pharmacological treatment became available and led to a significant decrease in the number of surgical procedures in many Western countries. The hypothesis of a causative role of benign prostatic enlargement and bladder outflow obstruction (BOO) in lower urinary tract symptoms (LUTS) was based on the association between prostate growth and symptoms of prostatism in elderly men and on the dramatic reduction of LUTS upon relief of obstruction. Careful investigation into the epidemiology of LUTS and BPH failed to confirm such an association and opened new perspectives in the pathophysiology of lower urinary tract dysfunction and symptoms. The observation that LUTS were equally distributed in male and female cohorts, when matched for age, moved attention away from the prostate and towards the urinary bladder and its aging-related disorders. When BPH surgery was developed, the management of the disease was aimed at preventing death from chronic renal failure, but the picture has changed and modern medical treatment is now aimed at improving the patient's quality of life. The increasing size of elderly populations in the Western world and the consequent financial constraints of national healthcare systems have raised the question of when pharmacological treatment of symptomatic BPH should be initiated. Retrospective and prospective analysis of various BPH populations and clinical studies has clearly defined the capacity of pharmacological treatment to reduce the incidence of complications of BPH, such as acute urinary retention and the need for surgery, but the cost/benefit ratio is unclear. Notwithstanding the limitations inherent in the experimental models, there is evidence from various animal models, investigating the pathophysiology of the urinary bladder in the presence of outflow obstruction, to indicate that a cause and effect relationship between BOO and bladder decompensation has been established and to support the hypothesis that permanent bladder damage may occur when the obstruction is not relieved early enough. Preliminary experimental evidence also suggests that alpha(1)-adrenoceptor antagonists may have a role in reducing the damaging effects of BOO on the urinary bladder. At present, there is no evidence to support the need for early pharmacological treatment of symptomatic BPH with no BOO beyond the obvious target of improving the patient's quality of life. The evidence for early treatment of BOO and the need to preserve bladder function is clear. Further experimental and clinical research is required to identify markers of early bladder damage and decompensation which can be used to select patients for early pharmacological treatment of BPH.

[Use of sildenafil in the chronic uremic patient]

BACKGROUND

Erectile dysfunction is one of the factors influencing negatively the quality of life of patients in hemodialytic treatment. The international literature shows that erectile dysfunction is present in 30% of patients with chronic renal failure and in 50% of patients undergoing dialytic treatment. Fertility, libido and erectile dysfunction, suffer progressive worsening with time, in spite of hemodialysis. The availability of a drug like Sildenafil can improve the quality of life of the patient and give him a normal sexual activity.

METHODS

Twenty patients between 29 and 51 years, were selected; 2 of these had been subjected to renal transplant, with a dialytic treatment time varying from 3 to 13 years. Before the treatment all the patients have been subjected to an andrological screening (testosterone, prolactin, penile color Doppler ultrasound) and proposed the IIEF test. Therapeutic strategy included the assumption of the drug in the days in which the patients were not subjected to dialysis, with an interval from 1 to 3 weeks between assumption and another. The dose was 25-50 mg. At the end of three months of therapy the patients were again subjected to the IIEF test.

RESULTS

All patients reported an improvement in sexual activity and sexual desire with very good repercussions on general and psychophysical conditions.

CONCLUSIONS

The results demonstrate at least that Sildenafil is also effective in uremic patients in dialytic treatment or after renal transplant and that it can therefore resolve one of the main problems for the normal development of the life of such patients.

[Hormonal markers of early-stage osteitis fibrosa in patients on hemodialysis]

The diagnosis of renal osteodystrophy is straightforward when the disease has reached an advanced stage and the pathology is extremely difficult to treat, whereas it is considerably more complex during the early stages. A study was carried out to assess the sensitivity of some biochemical, hormonal and instrumental markers in the early diagnosis of osteitis fibrosa in patients undergoing hemodialysis due to chronic renal insufficiency. Of these markers, the assay of whole molecule PTH appeared to be the most sensitive and specific biological marker.

[Use of ultrafiltration in refractory cardiac decompensation]

Traditional therapy for heart failure (diuretics, digitalic compound, vasodilators, inodilatory ACE-inhibitors) cannot arrest the progressive overloading of the circulatory system so that it is inevitable that a refractory stage to all forms of treatment will be reached when more specialised techniques, such as heart transplant and ultrafiltration will be needed. The paper reports the results obtained in 13 patients in ultrafiltration treatment for refractory heart failure: in the majority of these, a marked improvement in general conditions (edema, dyspnea) was recorded together with a regression from class 5 to class 3 NYHA in 5 patients, and to class 2 for others. The ultrafiltration method in spite of not altering the prognosis which remains negative in these patients, allow those waiting for heart transplant to survive and may improve their chances of surviving heart surgery.